News

Filter

Current filters:

None

46 to 55 of 96312 results

Added indication for Daiichi Sankyo’s Lixiana in Japan

Added indication for Daiichi Sankyo’s Lixiana in Japan

29-09-2014

The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi…

Cardio-vascularDaiichi SankyoJapanLixianaPharmaceuticalRegulation

Update: Negotiations on EU-Canada Free Trade Agreement concluded

Update: Negotiations on EU-Canada Free Trade Agreement concluded

29-09-2014

Canadian trade group Research-Based Pharmaceutical Companies (Rx&D) expressed its support to the government…

CanadaEuropeGenericsMarkets & MarketingPatentsPoliticsRegulation

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

Moshe Manor appointed president and chief executive of Protalix BioTherapeutics

Moshe Manor appointed president and chief executive of Protalix BioTherapeutics

29-09-2014

Israeli pharma company Protalix BioTherapeutics has appointed Moshe Manor as its new president and chief…

BoardroomIsraelPharmaceuticalPresident and chief executiveProtalix BioTherapeutics

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

US FDA approves Iluvien for diabetic macular edema

US FDA approves Iluvien for diabetic macular edema

28-09-2014

US ophthalmic drug specialist Alimera Sciences says that the US Food and Drug Administration has approved…

Alimera SciencesIluvienMedidurOphthalmicsPharmaceuticalpSividaRegulationTethadurUSA

46 to 55 of 96312 results

Back to top